A Late-Arriving but Welcome Advance in Sarcoma Therapy

N Engl J Med. 2024 Sep 5;391(9):854-855. doi: 10.1056/NEJMe2407116.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols* / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols* / adverse effects
  • Clinical Trials, Phase III as Topic
  • Doxorubicin* / administration & dosage
  • Doxorubicin* / adverse effects
  • Humans
  • Leiomyosarcoma* / drug therapy
  • Leiomyosarcoma* / mortality
  • Progression-Free Survival
  • Trabectedin* / administration & dosage
  • Trabectedin* / adverse effects
  • Treatment Outcome

Substances

  • Trabectedin
  • Doxorubicin